Policy Perspectives

Patient experience data (PED) are data providing information about patients’ experiences with a disease or condition, including experiences with disease symptoms, impacts, and

As we celebrate our 10 th anniversary of The Transforming Clinical Trials Initiative (TCTI) in 2026, we look forward to continuing our mission to improve the efficiency and

On October 22, 2025, the US Food and Drug Administration (FDA) released a final guidance document on Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for

LUNGevity Foundation’s Transforming Clinical Trials Initiative (TCTI) develops collaborative strategies to enhance innovation and patient access to safe and effective lung cancer

LUNGevity Foundation’s Transforming Clinical Trials Initiative (TCTI) develops collaborative strategies to enhance innovation and patient access to safe and effective lung cancer

The US Food and Drug Administration (FDA) Oncologic Drug Advisory Committee (ODAC) met on July 17th, 2025 to review the results of clinical trials DREAMM-7 and DREAMM-8 assessing